Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KMT2C is a Potential Biomarker of Anti-PD-1 Treatment Response in Metastatic Melanoma.

Frontiers in bioscience (Landmark edition) - 17 Mar 2022

Xie Kuixia, Peng Yonglin, Zhong Wenying, Liu Xinhua

Abstract excerpt

BACKGROUND: Metastatic melanoma (MM) represents a common malignancy with poor prognosis. Immune checkpoint inhibition (ICI), including PD-1 blockade, has been emerging as the popular therapeutic in MM for its durable treatment effect, but its response rate is still limiting. METHODS: We comprehensively analyzed the associations between KMT2C somatic mutation and the tumor microenvironment as well as the ICI...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Biomarkers, Tumor
Share to DNA-Binding Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Melanoma

Share to Mutation

Share to Programmed Cell Death 1 Receptor

Share to Tumor Microenvironment

Source

Identifiers

PMID: 35345335
DOI: 10.31083/j.fbl2703103

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KMT2C is a Potential Biomarker of Anti-PD-1 Treatment Response in Metastatic Melanoma.PMID 35345335Read ↗

KMT2A/C mutations function as a potential predictive biomarker for immunotherapy in solid tumorsSemantic proximity Read ↗

KMT2C mutation as a predictor of immunotherapeutic efficacy in colorectal cancer.Semantic proximity Read ↗

KMT2C is Potential Prognostic Biomarker and its Immune Regulating Roles in Pan-Cancer: A Comprehensive AnalysisSemantic proximity Read ↗

The Predictive Value of MAP2K1/2 Mutations on Efficiency of Immunotherapy in Melanoma.Semantic proximity Read ↗

Genomic alterations in KMT2 family predict outcome of immune checkpoint therapy in multiple cancersSemantic proximity Read ↗

Mutation status of the KMT2 family associated with immune checkpoint inhibitors (ICIs) therapy and implicating diverse tumor microenvironmentsSemantic proximity Read ↗

HSPG2 Mutation Association with Immune Checkpoint Inhibitor Outcome in Melanoma and Non-Small Cell Lung CancerSemantic proximity Read ↗

Multi-omics analysis of tumor mutation burden combined with immune infiltrates in melanoma.Semantic proximity Read ↗

Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma.Semantic proximity Read ↗

Significance of Tumor Mutation Burden in Immune Infiltration and Prognosis in Cutaneous MelanomaSemantic proximity Read ↗

Association of KMT2C/D loss-of-function variants with response to immune checkpoint blockades in colorectal cancer.Semantic proximity Read ↗

Identification of Prognostic Biomarkers of Cutaneous Melanoma Based on Analysis of Tumor Mutation Burden.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.